{"id":995896,"date":"2026-08-17T08:09:27","date_gmt":"2026-08-17T12:09:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/starling-oncology-launches-starling-nexus-a-technology-platform-built-to-optimize-oncology-provider-engagement-and-accelerate-high-quality-care-at-scale\/"},"modified":"2026-08-17T08:09:27","modified_gmt":"2026-08-17T12:09:27","slug":"starling-oncology-launches-starling-nexus-a-technology-platform-built-to-optimize-oncology-provider-engagement-and-accelerate-high-quality-care-at-scale","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/starling-oncology-launches-starling-nexus-a-technology-platform-built-to-optimize-oncology-provider-engagement-and-accelerate-high-quality-care-at-scale\/","title":{"rendered":"Starling Oncology Launches Starling Nexus\u2122, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale"},"content":{"rendered":"

\nCompany\u2019s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow
\n<\/h2>\n
\n

CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) — Starling Oncology\u2122 Inc. (NASDAQ: STLN), (\u201cSTLN\u201d or the \u201cCompany\u201d), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care\u2019s persistent challenges: NCCN compliance by the medical community and a fragmented and administratively burdensome prior authorization process for providers.<\/p>\n

Oncology treatment decisions are complex and time-sensitive for patients, yet prior authorization often depends on disconnected systems, resulting in delays and errors in care delivery. Starling Nexus brings these processes together in a single digital workflow designed specifically for oncology, connecting clinical decision support with utilization management to help providers and their teams navigate treatment approvals with greater clarity and consistency. Over time, Starling Nexus will also serve as the hub for integration of ancillary services such as pharmacy and clinical trials for patients who require these services.<\/p>\n

\u201cUtilization management should support rapid access to high-quality cancer care for patients and not add complexity to an already stressful treatment journey,\u201d said Jeffrey Langsam, DO, Chief Clinical Officer of Starling Oncology. \u201cWe built Starling Nexus around the realities physicians and their teams face every day. By bringing evidence-based clinical guidance and authorization into one workflow, we can reduce administrative friction and create a more connected approach to oncology care.\u201d<\/p>\n

\n Built for the Complexity of Oncology Care<\/strong>\n <\/p>\n

Starling Nexus brings critical capabilities into one oncology-specific experience:<\/p>\n